These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 6982707)
41. [Distribution of aromatic amino acid residues according to the character of their microenvironment and the dynamics of the conformational properties of the protein molecule C1q]. Ul'ianov VD; Mogutnova VA; Surovtsev VI; Shmatchenko NA; Sukhomudrenko AG Ukr Biokhim Zh (1978); 1989; 61(1):9-17. PubMed ID: 2787069 [TBL] [Abstract][Full Text] [Related]
42. Interaction of C1q with IgG1, C-reactive protein and pentraxin 3: mutational studies using recombinant globular head modules of human C1q A, B, and C chains. Roumenina LT; Ruseva MM; Zlatarova A; Ghai R; Kolev M; Olova N; Gadjeva M; Agrawal A; Bottazzi B; Mantovani A; Reid KB; Kishore U; Kojouharova MS Biochemistry; 2006 Apr; 45(13):4093-104. PubMed ID: 16566583 [TBL] [Abstract][Full Text] [Related]
43. The reaction between the complement subcomponent C1q, IgG complexes and polyionic molecules. Hughes-Jones NC; Gardner B Immunology; 1978 Mar; 34(3):459-63. PubMed ID: 640715 [TBL] [Abstract][Full Text] [Related]
44. Complement C1q binding affects spin-labeled heterosaccharides of rabbit antibodies in immune but not artificial immunoglobulin G aggregates. Winkelhake JL; Kusumi A; McKean L; Mandy WJ J Biol Chem; 1984 Feb; 259(4):2171-8. PubMed ID: 6199346 [TBL] [Abstract][Full Text] [Related]
45. [IgG-bound DNA and C1q-binding materials in iupus nephritis]. Koyama A; Narita M; Lshida H; Inage H; Sano M; Tojo S Nihon Jinzo Gakkai Shi; 1982 Mar; 24(3):267-74. PubMed ID: 6981719 [No Abstract] [Full Text] [Related]
46. Characterization of C1q by monoclonal antibodies. Heinz HP; Loos M Behring Inst Mitt; 1984 Nov; (76):42-58. PubMed ID: 6335397 [TBL] [Abstract][Full Text] [Related]
47. Critical aspects of the 125I-C1q binding assay for detecting immune complexes in tumor patients. Krieger G; Bause I; Kneba M; Kehl A; Nagel GA J Clin Lab Immunol; 1984 Jun; 14(2):87-92. PubMed ID: 6611419 [TBL] [Abstract][Full Text] [Related]
48. Macrophage C1q: characterization of a membrane form of C1q and of multimers of C1q subunits. Martin H; Heinz HP; Reske K; Loos M J Immunol; 1987 Jun; 138(11):3863-7. PubMed ID: 3495575 [TBL] [Abstract][Full Text] [Related]
49. C1q binding and C1 activation by various isolated cellular membranes. Storrs SB; Kolb WP; Olson MS J Immunol; 1983 Jul; 131(1):416-22. PubMed ID: 6602834 [TBL] [Abstract][Full Text] [Related]
50. Interaction of human C1q with IgG and IgM: revisited. Gadjeva MG; Rouseva MM; Zlatarova AS; Reid KB; Kishore U; Kojouharova MS Biochemistry; 2008 Dec; 47(49):13093-102. PubMed ID: 19006321 [TBL] [Abstract][Full Text] [Related]
51. The effects of cleavage of the inter-chain disulphide bonds of rabbit IgG on its ability to bind C1q. Sutton J; Alden JR; Easterbrook-Smith SB Biochim Biophys Acta; 1984 May; 787(1):39-44. PubMed ID: 6609719 [TBL] [Abstract][Full Text] [Related]
52. Cartilage proteoglycan interactions with C1q and the localization of aggregated IgG complexes in cartilage. Sparks K; Goetinck P; Ballow M Prog Clin Biol Res; 1982; 110 Pt B():113-23. PubMed ID: 6984760 [No Abstract] [Full Text] [Related]
53. New insights into the molecular mechanisms of classical complement activation. Kojouharova M; Reid K; Gadjeva M Mol Immunol; 2010 Aug; 47(13):2154-60. PubMed ID: 20542571 [TBL] [Abstract][Full Text] [Related]
54. Complement C1q-target proteins recognition is inhibited by electric moment effectors. Roumenina L; Bureeva S; Kantardjiev A; Karlinsky D; Andia-Pravdivy JE; Sim R; Kaplun A; Popov M; Kishore U; Atanasov B J Mol Recognit; 2007; 20(5):405-15. PubMed ID: 17929239 [TBL] [Abstract][Full Text] [Related]
55. Interaction of fibronectin with C1q and collagen. Effects of ionic strength and denaturation of the collagenous component. Ingham KC; Landwehr R; Engel J Eur J Biochem; 1985 Apr; 148(2):219-24. PubMed ID: 3872795 [TBL] [Abstract][Full Text] [Related]
56. [Changes in the ultrastructure of subcomponent C1q of human complement during spontaneous inactivation in diluted solutions]. Kozlov LV; Zinchenko AA; Sizoĭ MN; Kretova AF; Tikhonenko AS Bioorg Khim; 1985 Jan; 11(1):37-42. PubMed ID: 3872663 [TBL] [Abstract][Full Text] [Related]
57. In vivo degradation of rat C1q induced by intravenous injection of soluble IgG aggregates. Veerhuis R; van Es LA; Daha MR Immunology; 1985 Apr; 54(4):801-10. PubMed ID: 3872261 [TBL] [Abstract][Full Text] [Related]
58. S-sulfonation: a reversible chemical modification of human immunoglobulins permitting intravenous application. I. Physicochemical and binding properties of S-sulfonated and reconstituted IgG. Gronski P; Hofstaetter T; Kanzy EJ; Lüben G; Seiler FR Vox Sang; 1983; 45(2):144-54. PubMed ID: 6604365 [TBL] [Abstract][Full Text] [Related]
59. Stereospecific binding capacity of proteins on surfaces--simple mathematical models. Lundström I; Elwing H J Theor Biol; 1984 Sep; 110(2):195-204. PubMed ID: 6436583 [TBL] [Abstract][Full Text] [Related]
60. Studies on the chemical modification and potato (Solanum tuberosum) lectin and its effect on haemagglutinating activity. Ashford D; Menon R; Allen AK; Neuberger A Biochem J; 1981 Nov; 199(2):399-408. PubMed ID: 7340810 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]